Neurogene Inc.

IPO

Neurogene - Developing Purpose-built Genetic Medicines

Public · New York, United States · Founded 2018 · $183.5M raised

Headquarters
New York, New York
Employees
51–200
Founded
2018
Business Model
B2B
Total Funding
$183.5M
Last Round
$115.0M Series BDec 2020
Rounds
2
Type
Public

About

Neurogene is a clinical-stage gene therapy company advancing genetic medicines for rare neurological diseases, with its lead program NGN-401 targeting Rett syndrome using a proprietary EXACT technology platform designed to overcome dosage-sensitivity limitations of conventional gene therapy approaches.

Summary

Neurogene Inc. is a Biotech company based in New York, United States, founded in 2018. It has raised $183.5M in total across 2 rounds, most recently a $115.0M Series B round in Dec 2020. Investors include EcoR1 Capital, RTW Investments and Redmile Group.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Secondary MarketSecondary MarketNov 2024
$200.0M

Sign up to see all 4 rounds

Series A through Secondary Market — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Neurogene Inc. on Indexed.vc
<a href="https://indexed.vc/companies/neurogene-inc"><img src="https://indexed.vc/api/badge/company/neurogene-inc" alt="Neurogene Inc. on Indexed.vc" width="260" height="76" /></a>